| 000 | 01859 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516100016.0 | ||
| 264 | 0 | _c20121206 | |
| 008 | 201212s 0 0 eng d | ||
| 022 | _a1473-5628 | ||
| 024 | 7 |
_a10.1097/MNM.0b013e3283561837 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKhandani, Amir H | |
| 245 | 0 | 0 |
_aPrimary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. _h[electronic resource] |
| 260 |
_bNuclear medicine communications _cSep 2012 |
||
| 300 |
_a967-73 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aBenzenesulfonates _xadverse effects |
| 650 | 0 | 4 | _aBiological Transport |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdiagnostic imaging |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorodeoxyglucose F18 _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdiagnostic imaging |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMultimodal Imaging |
| 650 | 0 | 4 |
_aNeoadjuvant Therapy _xadverse effects |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 | _aPhenylurea Compounds |
| 650 | 0 | 4 | _aPositron-Emission Tomography |
| 650 | 0 | 4 |
_aPyridines _xadverse effects |
| 650 | 0 | 4 | _aSafety |
| 650 | 0 | 4 | _aSorafenib |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTomography, X-Ray Computed |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aCowey, C Lance | |
| 700 | 1 | _aMoore, Dominic T | |
| 700 | 1 | _aGohil, Harsh | |
| 700 | 1 | _aRathmell, Wendy Kimryn | |
| 773 | 0 |
_tNuclear medicine communications _gvol. 33 _gno. 9 _gp. 967-73 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MNM.0b013e3283561837 _zAvailable from publisher's website |
| 999 |
_c21878567 _d21878567 |
||